Polyphenols and Ulcerative Colitis: An Exploratory Study of the Effects of Red Wine Consumption on Gut and Oral Microbiome in Active‐Phase Patients

Abstract

Scope: This paper explores the effects of moderate red wine consumption on the clinical status and symptomatology of patients with ulcerative colitis (UC), including the study of the oral and intestinal microbiome. Methods and results: A case control intervention study in UC patients is designed. Intervention patients (n = 5) consume red wine (250 mL day −1 ) for 4 weeks whereas control patients (n = 5) do not. Moderate wine consumption significantly (p < 0.05) improves some clinical parameters related to serum iron, and alleviates intestinal symptoms as evaluated by the IBDQ-32 questionnaire. 16S rRNA gene sequencing indicate a non-significant (p > 0.05) increase in bacterial alpha diversity after wine intervention in both saliva and fecal microbiota. Additional comparison of taxonomic data between UC patients (n = 10) and healthy subjects (n = 8) confirm intestinal dysbiosis for the UC patients. Finally, analysis of fecal metabolites (i.e., phenolic acids and SCFAs) indicates a non-significant increase (p > 0.05) for the UC patients that consumed wine. Conclusions: Moderate and regular red wine intake seems to improve the clinical status and symptoms of UC patients in the active phase of the disease. However, studies with a greater sample size are required to achieve conclusive results.

Gut Microbiota and Inflammation Modulation in a Rat Model for Ulcerative Colitis after the Intraperitoneal Administration of Apigenin, Luteolin, and Xanthohumol

“…Conversely, the genera Clostridia UCG-014 and Enterorhabdus [ 26 , 43 ] were increased in these luteolin and xanthohumol cohorts ( Table 3 , Supplementary Figure S4 ). In particular, the genus Enterorhabdus belongs to the polyphenol-degrading family Eggerthellaceae (phylum Actinomycetota ), which is associated with health status and reported to potentiate the production of the previously mentioned bioactive phenolic metabolites [ 26 , 44 , 45 ].…”

Moderate wine consumption and inflammatory bowel diseases. Impact in the gut and oral microbiome

“…All these outcomes led to an improvement in the quality of life of the participants of this exploratory study as revealed by the IBDQ-32 questionnaire. Although studies with a greater sample size are required, the integrated vision provided in this study has allowed us to establish the most complete scientific evidences to date on the impact of moderate wine consumption in IBD patients, as well as on the oral and intestinal microbiome and its physiological relevance [2,15].…”

“…The ethanol content in the wine was 13.5% and the total phenolic content reached 2500 mg of gallic acid equivalents/L as determined by the Folin-Ciocalteau method. The polyphenol profile of the wine was analysed by UPLC-ESI-MS/MS [2].…”

The INHABIT (synergIstic effect of aNtHocyAnin and proBIoTics in) Inflammatory Bowel Disease trial: a study protocol for a double-blind, randomised, controlled, multi-arm trial

“…(39,40) The primary comparison of interest is between the combined intervention versus control. Assuming a mean change in the IBDQ-32 score of 16 ± 20 estimated from previous literature, (41)(42)(43)(44) αsignificance of 0⋅05 and power 95 %, a sample size of n 19 per arm is required with effect size of 0⋅8. To allow for ∼25 % drop-out, given the duration of this trial and based on previous literature, (45)(46)(47) n 25 participants will be recruited to each arm.…”